Good news! CE certificate for Etta X-Porator F1!

CE certificate has been obtained for Etta Flow Electroporator X-Porator F1, which indicates that Etta Flow Electroporator X-Porator F1 has successfully passed strict tests and assessments, meeting ...

2019-04-18 11:52

Within two months, we have received three orders of Etta flow electroporator X-Porator F1!

Etta flow electroporator X-Porator F1 is the result of four years of painstaking R&D and manufacturing of Etta Biotech. Less than two months after its launch, it has received orders from three antibody drug companies in Suzhou, Beijing and Hangzhou, showing users' affirmation of its performance! The main performance of Etta flow electroporator X-Porator F1 is the transient transformation of a large number of engineered cells to produce antibody proteins, which has a great application prospect in the field of antibody drug development and production. In the user trial, the expression level of diplasmid system hIgG in CHO cells was 2-5 times higher than that in chemical transfection from one user. The expression level of single-chain anti-somatic particles with low expression by chemical transfection in CHO cells was increased by more than 40 times from another user.

2018-12-13 13:40

Etta has completed A-round of financing, dedicated to creating world-class electrotransfection products to help cancer treatment

On November 19, 2018, Etta biotech Co., Ltd. (Hereinafter referred to as "Etta Biotech") and Zhongshan Beisen Medical Fund officially signed an investment agreement, announcing the successful completion of the A-round financing of tens of millions of RMB. Beisen Medical Fund is the sole investor in this round of financing. It is Etta’s investment obtained from another well-known investment institution in the industry, after the famous angel investor Li Jing and Jiangsu Qianrong Financing Capital.

2018-11-19 11:36

< 1234...8 >

Share